Manuela Loidl

Title: Manuela Loidl: Innovator in Monoclonal Antibody Research

Introduction

Manuela Loidl is a prominent inventor based in Korneuburg, Austria. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, her work focuses on innovative methods for treating tumors.

Latest Patents

Manuela Loidl's latest patents include groundbreaking inventions related to the Lewis Y antigen. The first patent describes a method of treating Lewis Y-expressing tumors using a monoclonal antibody or its derivatives. This invention is characterized by an Fc region that carries a bi-sected hybrid type N-glycosylation pattern, resulting in at least a tenfold increase in antibody-dependent cellular cytotoxicity (ADCC) and a reduction of at least 10% in complement-dependent cytotoxicity (CDC) activity. The second patent also involves an N-glycosylated antibody that recognizes the Lewis Y antigen, featuring similar enhancements in ADCC and CDC activity.

Career Highlights

Throughout her career, Manuela Loidl has worked with notable companies in the biotechnology sector. She has been associated with Greenovation Biotech GmbH and Meridian Biopharmaceuticals GmbH, where she has contributed her expertise in antibody research and development.

Collaborations

Manuela has collaborated with esteemed colleagues, including Manfred Schuster and Gottfried Himmler, further enhancing her research and innovation in the field.

Conclusion

Manuela Loidl's contributions to monoclonal antibody research have positioned her as a key figure in biotechnology. Her innovative patents and collaborations reflect her commitment to advancing medical treatments for cancer.